Abstract Ovarian cancer (OVC) remains the most lethal gynecological malignancy in the world due to the combined lack of early-stage diagnostics and effective therapeutic strategies. The development and application of advanced proteomics technology and new experimental models has created unique opportunities for translational studies. In this study, we investigated the ovarian cancer proteome of the chicken, an emerging experimental model of OVC that develops ovarian tumors spontaneously. Matched plasma, ovary, and oviduct tissue biospecimens derived from healthy, early-stage OVC, and late-stage OVC birds were quantitatively characterized by label-free proteomics. Over 2600 proteins were identified in this study, 348 of which were differentially expressed by more than twofold (p≤0.05) in early-and late-stage ovarian tumor tissue specimens relative to healthy ovarian tissues. Several of the 348 proteins are known to be differentially regulated in human cancers including B2M, CLDN3, EPCAM, PIGR, S100A6, S100A9, S100A11, and TPD52. Of particular interest was ovostatin 2 (OVOS2), a novel 165-kDa protease inhibitor found to be strongly upregulated in chicken ovarian tumors (p=0.0005) and matched plasma (p=0.003). Indeed, RT-quantitative PCR and Western blot analysis demonstrated that OVOS2 mRNA and protein were also upregulated in multiple human OVC cell lines compared to normal ovarian epithelia (NOE) cells and immunohistochemical staining confirmed overexpression of OVOS2 in primary human ovarian cancers relative to non-cancerous tissues. Collectively, these data provide the first evidence for involvement of OVOS2 in the pathogenesis of both chicken and human ovarian cancer.
Introduction
Ovarian cancer (OVC) is the most lethal gynecological cancer in the Western World due to a combination of ineffective early-stage detection methods and late-stage treatment strategies [1] . Approximately 22,000 women in the USA were diagnosed with OVC in 2013, approximately 70 % of which presented with advanced stages of the disease (stages III and IV) when surgical intervention and chemotherapeutic treatment are least effective [2] . Currently, early detection is the single most important determinant for survival with 5-year mortality rates less than 10 % for women with stage I OVC. Thus, significant effort has been focused on identifying the Electronic supplementary material The online version of this article (doi:10.1007/s00216-015-8862-4) contains supplementary material, which is available to authorized users.
OVC-initiating molecular events that could serve as important early-stage markers for OVC such as cancer antigen-125 (CA-125), human epididymis protein 4 (HE-4), and transvaginal ultrasound [3] and novel therapeutic targets for improved patient outcomes.
Investigating the onset and progression of OVC has proven very challenging due to tumor heterogeneity, the paucity of early-stage primary tissues, and few natural animal models that faithfully recapitulate the pathophysiology of the human disease [4] [5] [6] . In recent years, the chicken has emerged as a unique experimental model that develops OVC spontaneously with morphological and molecular similarities to humans [7, 8] . The prevalence of spontaneous OVC in the chicken can exceed 35 % after 2 years of age depending on the genetic strain and ovulation rate (i.e., unfertilized egg production) [9] , the latter being consistent with the incessant ovulation theory [10] . Important molecular-level similarities include CA-125 expression [11] , frequency of p53 mutations [12] , Ecadherin upregulation [13] , and gene expression patterns [14] . Thus, the chicken provides a powerful experimental model for investigating the molecular events that lead to the onset and progression of spontaneous OVC with powerful bioanalytical tools such as mass spectrometry-based proteomics [15] . In a recent study, we measured the plasma proteome intra-individual variability of two chickens over a 1-year period: one bird was healthy with no visible neoplasms and the second bird developed late-stage OVC [16] , followed by targeted SRM to quantify a candidate biomarker, ovostatin 2 (OVOS2) [17] . Although these early studies identified OVOS2, we were only able to identify approximately 120 proteins from plasma due to interference from high abundant proteins (e.g., albumin) and the lack of any standardized depletion reagents that are common in human and mouse plasma proteomics studies.
Herein, we report the first in-depth proteomics analysis of ovarian cancer in the chicken with matched plasma, ovary, and oviduct tissues from healthy, early-stage OVC, and latestage OVC birds. A total of 248 proteins in plasma, 2680 proteins in the ovaries/ovarian tumors, and 1452 proteins in the oviduct tissues were identified with high confidence using high-performance mass spectrometry-based proteomics (LC-MS/MS). Among the 392 differentially regulated proteins in chicken OVC, over 70 of them have been associated with cancer in human studies. Within these 70 cancer-related proteins, we observed 5 known human OVC-related proteins including B2M, EPCAM, TPD52, CLDN3, and S100A6. In addition to these known OVC-related proteins, four members of the MEROPS I39 protease inhibitor family were identified including OVOS2 which was significantly upregulated in late-stage OVC plasma (p<0.05) and ovary (p<0.01). We then investigated the expression levels of human OVOS2 in primary tumor specimens and OVC cell lines. Strong OVOS2 immunohistochemical staining of stage III high-grade serous ovarian cancer tumors was observed for malignant epithelial cells compared to surrounding normal tissues. Furthermore, OVOS2 messenger RNA (mRNA) and protein were also overexpressed in multiple human OVC cell lines but not in normal ovarian epithelial (NOE). Collectively, these data provide convincing evidence for a conserved, yet undefined, role for OVOS2 in ovarian cancer of the chicken and human.
Experimental
Animal care, biospecimen collection, and pathology All animals were cared for in accordance with North Carolina State University IACUC regulations. Details of the sample collection, sample storage, bird mortality, and pathology were described elsewhere [16] . Briefly, approximately 2 mL of blood was drawn from 150 age-and strain-matched Bovans White birds every 3 months for 1 year starting at 2.5 years of age into EDTA tubes followed by centrifugation at 3000×g for 3 min at 10°C, plasma collection, and storage at −80°C. After the final blood draw at 3.5 years of age, the remaining birds were euthanized followed by ovary and oviduct tissue collection. Tissues were preserved for both pathological (formalin fixation) and proteome (LN 2 snap frozen) characterization. Tissue slides of 5 μm were stained with hematoxylin and eosin (H&E) and assessed by a board-certified veterinary pathologist.
Chicken tissue lysate preparation
Frozen ovary and oviduct tissues were removed from −80°C storage, weighed (frozen), and then placed on ice. Lysis buffer (50 mM Tris pH 7.8, 8 M urea, 2 M thiourea, 10 mM EDTA, 10 mM DTT, and 0.001 % sodium azide) was added to each frozen tissue sample at a concentration of 0.2 mg/mL. The samples were then homogenized using an OMNI TIP Homogenizing Kit (Omni International) for 1 min followed by the addition of 2 % (w/v) sodium dodecyl sulfate. Samples were shaken for 1 min, incubated on ice for 5 min, the cycle repeated twice more, and then centrifuged for 30 min at 14,000 rpm. The soluble fractions were removed from the centrifuge tube without disrupting the cellular debris pellet or the top lipid layer. The extracts were then stored at −80°C until immediately prior to 1D SDS-PAGE.
SDS-PAGE and in-gel digestion
The plasma samples from all nine birds were thawed, diluted 1:10 (v:v) with 50 mM Tris-HCl (pH 6.8), and then combined 1:1 (v:v) with freshly prepared 2-mercaptoethanol/Laemmli (Bio-Rad, Hercules, CA, USA) loading buffer. The ovary and oviduct lysates were thawed, vortexed, diluted 1:5 (v:v) with 50 mM Tris-HCl (pH 6.8), and then combined 1:1 (v:v) with freshly prepared 2-mercaptoethanol/Laemmli (Bio-Rad, Hercules, CA, USA) loading buffer. The resulting solutions were then heated at 95°C for 5 min, and then all three samples were analyzed on 12.5 % Tris-HCl precast gel (Bio-Rad Criterion 12+2 well format), run at 200 V for approximately 50 min, and then stained with Coomassie G-250 (Bio-Rad). The total protein concentrations for the plasma samples translated to gel loadings ranging from 20 to 32 μg based on Bradford assay. Attempts to quantify the total protein levels in the ovary and oviduct lysates were not successful due to the high levels of urea, thiourea, and SDS. Thus, each gel lane was loaded with 30 μL each of lysate proteome solution.
In-gel digestion was performed as previously described [16] in a laminar flow hood by cutting 36 even gel bands per lane (2 mm×7 mm) using a grid cutter (The Gel Company, San Francisco, CA). The 36 gel bands/lane were combined into 12 fractions (each fraction=3 neighboring bands) from the plasma and ovary gel lanes, and the top 12 gel bands were combined into 4 fractions from the oviduct gel lanes into individual vials for in-gel digestion (GeLC [16, 18] ). At the conclusion of the trypsin digestion, the tryptic peptide solution was reduced to dryness in a Speedvac and stored at −80°C.
LC-MS/MS
A nanoLC-2D (Eksigent Technologies, Dublin, CA) was coupled to a LTQ-FT-XL (Thermo Scientific, San Jose, CA) using a vented column configuration [19] . The vented column consisted of a 75 μm×5 cm trap (IntegraFrit: New Objectives, Woburn, MA) coupled to a 75 μm×15 cm column (PicoFrit: New Objectives, Woburn, MA). Both the trap and analytical column were self-packed with Magic C18AQ stationary phase Mass spectrometric analysis was performed on a 7T LTQ-FT Ultra (ThermoFisher) with a pulse sequence consisting of a broadband acquisition in profile mode followed by eight datadependent MS/MS events in the ion trap. The LTQ-FT was mass calibrated with a target AGC limit of 1×10 6 every 40 LC-MS/MS runs (~2.5 days). The full scan was collected at 400-1600 m/z with a resolving power set at 100,000 FWHM at m/z=400. The dynamic exclusion time was set to 3 min.
Data analysis
LC-MS/MS data was searched against a concatenated targetreverse chicken database (IPI ver.3.74) with Homo sapiens keratin, keratin-related proteins, and porcine trypsin included. Mascot Distiller (ver. 2.3.2, Matrix Science, Boston, MA) was used to generate peaks lists, and then Mascot Daemon to perform the searches. Carbamidomethyl (C) was set as a fixed modification and deamidation (NQ), oxidation (M), and carbamyl (K and Nterm) were set as variable modifications. Additional search parameters included a maximum of two missed cleavages, peptide tolerance of ±5 ppm, and MS/MS tolerance of ±0.6 Da. Protein grouping, statistical filtering (1 % false discovery rate), and quantification of Mascot DAT files were accomplished using ProteoIQ (NuSep, Athens, GA, ver 2.3.01), a spectral counting label-free software package that uses a combination of Peptide/ Protein Prophet [20, 21] and PROVALT [22] .
The spectral counts (SpCs) for each tissue type were first normalized within each sample (between technical replicates) followed by normalized across samples (between birds) to generate normalized SpC (NSpC) values for each protein. The NSpC data was then filtered to include proteins with a total of at least 5 NSpCs per sample for further quantitative analysis. Data imputation was implemented for the NSpC plasma and ovary data; normalized spectral abundance factors (NSAF) were subsequently calculated, natural log transformed (lnNSAF), and analyzed for goodness of fit [23] . The optimal imputement values were 1.0 and 0.7 for plasma and ovary datasets, respectively. Student's t test was used to determine statistical significance of differential protein expression.
Immunohistochemistry
The paraffin-embedded human ovarian cancer blocks were pre-existing specimens obtained from the VCU Tissue & Data Acquisition & Analysis Core. These samples had patient consent for use in scientific research but were not collected specifically for the present work. The use for OVOS2 study was approved by the Virginia Commonwealth University Human Subjects Committee. Immunohistochemical staining (IHC) of paraffin-embedded sections was conducted with a rabbit polyclonal antibody against OVOS2 N-term amino acid 99-128 (Abgent; San Diego, CA, USA) using a standard procedure as described previously [24] .
Human cell lines
The sources and culture conditions of the 11 human ovarian cell lines (Caov-3, SKOV3, HEY, ES-2, Dov-13, OVCA420, OVCA429, OVCA432, OVCA433, A2780, and A2780CP) and normal ovarian epithelial cell cultures (NOE001 and NOE002) were described previously [25, 26] . The cells in early passages were maintained in culture for less than 4 weeks before isolation of total cellular RNA with TRIzol following the protocol of the manufacturer (Invitrogen). OVOS2 expression in OVCA432 cells was knocked down by lentiviraltransduced short hairpin RNA (shRNA) (pGreenPuro, System Biosciences) carrying 5′-CAGGCCTGATATTAATAGCAAT-3′ (OVOS2-shRNA1), 5′-GTTCTCCTACCTAAGAAGGC A-3′ (OVOS2-shRNA2), or a non-targeting control sequence (ctrl-shRNA).
RT-qPCR
Expression levels of human OVOS2, A2M, A2ML1, and OVOS1 mRNA in each cell line were measured by RT-qPCR. Complementary DNA (cDNA) was synthesized from RNA (1 μg, random primers), using the High-Capacity cDNA Reverse Transcription Kit from Applied Biosystems. Relative expression levels of target genes were determined using the gene-specific probes for OVOS2 (Hs02384746), A2M (Hs00929971), A2ML1 (Hs00405670), and OVOS1 (Hs01393981), the TaqMan Universal PCR Master Mix, and the 7900HT Real-Time PCR System (Applied Biosystems). The results were normalized to the levels of GAPDH and presented as per mil of GAPDH. Student's t test was used to determine statistical significance of gene transcript levels in ovarian cancer cell lines relative to NOE002.
Western blot analysis
Whole-cell lysates were prepared with cell lysis buffer (Cell Signaling Technologies, MA, USA), separated on SDS-PAGE electrophoresis, and transferred to PVDF membrane (BioRad, Hercules, CA). Blots were probed with rabbit anti-GAPDH (Cell Signaling) or a custom affinity purified rabbit polyclonal anti-OVOS2 antibody (GenScript) raised against the OVOS2 sequence EGAKASKQGVLDLP (AA 911-924). Immunocomplexes were visualized with the enhanced chemiluminescence detection kit from Amersham.
Results and discussion
Quantitative proteomics analysis of ovarian cancer in the chicken A large-scale biorepository of longitudinal plasma samples and matched tissues from the chicken was established from 150 age-matched B-strain birds over a 1-year period (2.5 to 3.5 years of age) [16] . A total of 73 birds were still living at the conclusion of the study; following necropsy, we found 52 birds were healthy without any visible neoplastic lesions, three birds had tumors localized to the ovary, two birds had tumors on the ovary and neighboring tissues without oviductal involvement, and 13 birds had tumors on both the ovary and oviduct that had spread to neighboring tissues (note: three birds had tumors with origins other than the ovary). A total of nine birds were selected from this population including three random Bhealthy^birds with no visible lesions that were producing eggs (birds 1-3), three Bearly-stage OVC^birds (birds 4-6), and three Blate-stage OVC^birds (birds 7-9) (Fig. 1a) . Three sets of matched samples from these nine birds (Fig. 1a) were selected for analysis including plasma (drawn immediately prior to necropsy at 3.5 years of age), ovary, and oviduct tissues.
Representative one-dimensional (1D) gels for plasma, ovary, and oviduct tissue lysates are shown in Fig. 1b including molecular weight markers (left) and excised band fractions for each sample type (right). Excised bands were processed for ingel digestion and analyzed by LC-MS/MS (GeLC), and the number of unique proteins identified in each sample plotted as a function of bird ID (Fig. 1c) . Importantly, the entire gel lane for both plasma and ovary samples was processed for triplicate LC-MS/MS analysis whereas only the top four gel fractions (high molecular weight) were processed and analyzed by LC-MS/MS as single runs. The oviduct samples were processed and analyzed differently to rapidly assay the high molecular weight bands to establish the presence or absence of the MEROPS I39 family of protease inhibitors which are potentially important in human OVC (vide infra). The GeLC analysis from all plasma, ovary, and oviduct samples identified 248, 2680, and 1452 proteins, respectively, with proteome overlap for the plasma, ovary, and oviduct proteins shown in Fig. 1d . The 1D gels for plasma, ovary, and oviduct samples from all nine birds, proteins identified per gel lane, and proteome overlap as a function of phenotype are given in Fig. S1 in the Electronic Supplementary Material (ESM). A complete list of all proteins identified in this study is given in Table S1 in the ESM.
The raw plasma and ovary proteomics datasets were normalized prior to quantitative analysis and biological interpretation. The oviduct gel fraction samples were analyzed once by LC-MS/MS rather than in triplicate; thus, quantitative analysis was not performed. The spectral count (SpC) data [27] were initially normalized within each sample and then normalized between samples (NSpC) to account for sampling differences that are typical for heterogeneous biospecimens. After normalization, we filtered the plasma and ovary datasets by including only those proteins with 5 NSpCs in at least one sample which was previously shown to be the limit of SpC quantitation [28] . The 5 NSpC filtering reduced the number of quantifiable proteins in plasma from 248 to 237 and in the ovarian tissue data from 2680 to 2307. We then empirically determined the optimum imputement values (i.e., those that gave the most normal distributions) for plasma and ovary datasets by varying the NSpC values by 0.1 from 0.5 to 1.5 followed by abundance factor normalization (NSAF) and natural log transformation (lnNSAF) [23] . The lnNSAF data with different imputement values were then fitted and analyzed by goodness of fit in JMP 10.0. The minimal imputement values that gave the best fit were 1.0 and 0.7 for plasma and ovary, respectively. LnNSAF datasets for plasma and ovary with different imputement values are given in ESM Fig. S2 and ESM Fig. S3 , respectively.
Student's t test was then used to determine the statistical significance of each protein expression level in early-and latestage OVC relative to healthy birds. Volcano plots for plasma (Fig. 2a) and ovary (Fig. 2b) show the −log 10 p values for each protein vs. the respective log 2 early OVC NSAF/healthy NSAF (blue) and log 2 late OVC NSAF/healthy NSAF (red) expression levels. We used a twofold (p value≤0.05) cutoff to segregate significant differentially regulated proteins in OVC vs. healthy birds. The number of proteins in each cutoff region for early-and late-stage OVC is denoted in the top left and right corners of Fig. 2a, b . For example, 70 and 121 proteins were significantly down-and upregulated, respectively, in early-stage OVC ovarian tumor tissues relative to healthy ovary tissues. Furthermore, 144 and 89 proteins were significantly down-and upregulated, respectively, in late-stage OVC ovarian tumor tissues relative to healthy ovary tissues. Overall, 44 proteins in OVC plasma (44/237=19 %) and 348 proteins in ovarian tumors (348/2307=15 %) were found to be ≥2-fold differentially expressed (p value≤0.05). The Venn diagram in Fig. 2c shows the overlap between the 44 differentially expressed proteins in early-vs. late-stage OVC plasma with 19 proteins significantly up-or downregulated in both stages of OVC. The second Venn diagram in Fig. 2d shows the overlap between the 348 differentially expressed proteins in earlyvs. late-stage ovarian tumor tissues with 76 proteins significantly up-or downregulated in both stages of the tumor. A full list of differentially expressed proteins (p value≤0.05) in both OVC plasma and ovarian tumor tissues is given in Table S1 in the ESM.
Cancer-related candidate protein biomarkers in chicken ovarian cancer
There have been many candidate protein biomarkers identified for cancers [29] that are conveniently catalogued in the interactive The Human Protein Atlas [30] . There are 1703 cancer-related genes listed in The Human Protein Atlas, of which 1053 are identified as candidate biomarkers. We compared the differentially regulated chicken OVC proteins to the 1053 candidate biomarker genes to assess the translational potential of the chicken model. Within the 392 differentially regulated proteins from the chicken in both OVC plasma and ovarian tumors, we identified 73 cancer-related protein biomarkers common between the chicken and human (Table 1) . Of the 73 proteins, 49 were upregulated and 24 were downregulated in OVC of the chicken. Within the 49 upregulated proteins, seven were found exclusively in plasma (bold) and two were found in both plasma and ovarian tissues (bold and underlined). Within the 24 downregulated proteins, two were found exclusively in plasma (bold) and one was found in both plasma and ovarian tissues (bold and underlined).
A number of proteins listed in Table 1 are associated with human ovarian cancer. We generated a list of OVC-specific genes in humans that were known to be differentially expressed from three sources: TCGA study [31] , Polanski et al. [29] , and Emmanuel et al. [32] . Five genes significantly upregulated in Table 1 are also upregulated in human OVC including B2M, CLDN, EPCAM, S100A6, and TPD52. B2M (beta-2 microglobulin) is a 12-kDa protein that is part of major histocompatibility complex I [33] . Altered levels of B2M have been observed in a number of cancers [34] [35] [36] including OVC where it is measured as part of the OVA1 test for prognostic evaluation of OVC patients following surgical removal of tumors and chemotherapeutic treatment [37, 38] . CLDN3 is a 23-kDa tight junction protein that forms the extracellular interface between healthy epithelial cells. CLDN3 is frequently upregulated in primary ovarian cancer tumors and cell lines [39, 40] . The epithelial cell adhesion molecule (EPCAM) is a 34-kDa cell surface protein that maintains undifferentiated stem cells and contributes to cancer cell proliferation [41] [42] [43] . S100A6 is a 12-kDa calcium-binding protein that is involved in several types of inflammation responses. S100A6 levels in plasma were recently shown to predict tumor burden in a xenograft mouse model of ovarian cancer [44] . Tumor protein D52 (TPD52) is a 25-kDa protein that is consistently upregulated in many cancers, yet its function is not well understood. Increased TPD52 protein expression in NIH3T3 cells and LnCaP cells showed increases in cell proliferation, anchorage independence, and tumorigenicity [45] .
Cancer antigen 125 (CA-125) and human epididymis protein 4 (HE-4) are both Food and Drug Administration (FDA)-approved biomarkers for ovarian cancer [1] . Given the importance of CA-125 and HE-4 in human OVC, we searched the chicken proteomics data for these proteins. Human CA-125 is a 2-MDa mucin expressed from the MUC16 gene that is overexpressed and then shed from the membrane surface of tumor cells into the bloodstream. We did not detect protein(s) in this study that aligned with human CA-125 although we did detect two mucins: MUC (Bmucin-like^) and MUC5B. Ovomucin α-subunit (MUC5B), an abundant protein in egg [46] , was found to be upregulated in the late-stage OVC tumor tissues, detected with 49 % sequence coverage in oviduct tissues and not detected in any of the plasma samples. Chicken MUC5B was BLAST searched against the Human UniProt database and resulted in a 45 % sequence identity to MUC5AC (P98088), a gel-forming protein found in gastric and respiratory tract epithelia [47] . Abherrant regulation of MUC5AC has been observed in several cancers [48] [49] [50] [51] including ovarian neoplasms [51, 52] . Thus, the upregulation of MUC5B in the late-stage OVC tissues of the chicken agrees with earlier OVC studies in humans. We did not find evidence for the chicken orthologue to HE-4 (WFDC2) in the chicken proteomics dataset.
Additional markers that have been evaluated alone or in combination with CA-125 and HE-4 include CA-19-9, CA-15-3, CEA, B2M, ApoA1, ApoC3, TTR, TF, IGF2, EGFR, CRP, MYO, OPN, IL-6, and IL-18 [38] . Among this group of potential biomarkers, ApoA1, B2M, TTR, TF, and CRP were identified in the chicken. Apolipoprotein A1 (ApoA1), B2M, transthyretin (TTR), and transferrin (TF) along with CA-125 are measured in the multiplexed OVA1 test for monitoring women after OVC diagnosis. In the OVA1 test, plasma levels for ApoA1, TTR, and TF are lower whereas B2M and CA-125 levels are increased in women with OVC [37] . Log 2 OVC/healthy expression levels for B2M in plasma were 0.44 (p=0.1055) for early-stage birds and 1.32 (p=0.0002) for late-stage birds which correlates with the OVA-1 test. TF levels in plasma are lower in both early-and late-stage OVC plasma but not statistically significant (log 2 early OVC/ healthy=−0.11, p=0.2350; log 2 late OVC/healthy=−0.14, p=0.2619). ApoA1 and TTR were upregulated in OVC plasma samples which is opposite the OVA1 values for human OVC. However, the levels for both ApoA1 (log 2 early OVC/ healthy=0.67, p=1.8E−6; log 2 late OVC/healthy=0.32, p= 0.0025) and TTR (log 2 early OVC/healthy=0.34, p=0.0300; log 2 late OVC/healthy=0.45, p=0.0425) were less than twofold increases. C-reactive protein (CRP) is a 23-kDa acutephase protein synthesized in the liver which increases in concentration by as much as 1000-fold in response to inflammation [53] . The upregulation of CRP in cancer is well established [54, 55] including OVC [56, 57] ; thus, we would expect CRP to increase in the chicken with the OVC stage. The label-free data for plasma supports this acute-phase response in the chicken with increased severity of the disease where CRP is 1.4-fold higher (p=0.0101) in early-stage OVC and 1.7-fold higher (p=0.0005) in late-stage OVC relative to healthy plasma levels. Overall, the quantitative proteomics analysis of chicken OVC agrees with previously observed human protein expression levels.
MEROPS I39 protein family expression in chicken ovarian cancer
OVOS2 is a predicted member of the MEROPS I39 family of protease inhibitors [58] that includes alpha-2 macroglobulin (A2M), pregnancy zone protein (PZP), alpha-2 macroglobulin like 1 and 2 (A2ML1 and A2ML2), and ovostatin 1 (OVOS1) which is one of the most abundant proteins in egg white [59] [60] [61] [62] [63] . The elevated levels of OVOS2 in our previous studies [16, 17] and a recent report on elevated levels of A2M in chicken OVC at the transcript level [64] led us to evaluate the expression levels of all MEROPS I39 protease inhibitors in healthy and neoplastic plasma, ovary, and oviductal tissues. The six members of the MEROPS I39 protease inhibitor family in the chicken clustered on the q-arm of chromosome 1 including A2ML1, A2ML2, A2M, LOC425756, OVOS1 (OVST), and OVOS2 (OVSTL) (Fig. 3a) . These proteins exhibit broad substrate specificity for all four classes of proteases and in some human studies have been implicated in tumorigenesis. We detected each protein in at least one tissue type with the exception of LOC425756 (Table 2 ). A2ML1 and OVOS1 were only detected in the oviduct with high sequence coverages (~50 %) and SpCs (>60 SpCs/sample) in birds 1-3 and 7 (Table 2 and ESM Table S1 ). A2M and A2ML2 were detected in all three tissue types yet their levels were drastically different for birds 1-3 and 7. A2M levels were high (>100 SpCs/sample) in those birds and low in birds 4-6, 8, and 9 whereas the inverse was true for A2ML2. These observations can be explained given that birds 1-3 and 7 were producing eggs (i.e., ovulating) at the time of necropsy (birds 4-6, 8, and 9 were out of production, i.e., anovulatory) which is in agreement with the proteomics characterization of chicken egg white [63] . OVOS2 is a 165-kDa protein identified and validated in our earlier proteomics studies of ovarian cancer in the chicken [16, 17] . In the present study with a higher level of protein fractionation and matched tissue analysis, we were able to detect OVOS2 with an overall sequence coverage >30 % ( Table 2 and ESM Table S1 ). OVOS2 levels were upregulated by more than 60-fold in late-stage OVC plasma (p=0.003) and tumor tissues (p=0.0005). Unlike the other I39 protease inhibitors in Table 2 , OVOS2 levels appear to correlate with the stage of OVC rather than the egg production status. Furthermore, OVOS2 was only detected in late-stage OVC oviduct tissues. Although we were unable to detect OVOS2 in early-stage OVC samples using label-free proteomics which would strengthen its potential as an early-stage OVC marker, we were interested in pursuing this candidate marker in human OVC. Interestingly, the MEROPS I39 family in chickens on chromosome 1 shows a high degree of conserved synteny with human chromosome 12 ( Fig. 3a and ESM Fig. S4 ) [65] . Chicken OVOS2 sequence BLAST analysis against the human protein database showed human OVOS2 (Q6IE36) gave the highest sequence identity at 45 % (Fig. 3b) . Based on these results, we sought to establish the expression levels for OVOS2 in human ovarian cancer to determine translational potential as a diagnostic biomarker.
OVOS2 is upregulated in human ovarian cancer
To assess the presence of OVOS2 in human OVC, we first measured OVOS2 mRNA in 11 human OVC cell lines and NOE cells by RT-qPCR. The qPCR results are shown in Fig. 4a with the OVOS2 mRNA levels normalized to Ct values of GAPDH. Importantly, the qPCR product for OVOS2 mRNA analysis spanned an exon to prevent the detection of genomic DNA. OVOS2 mRNA levels in all OVC cell lines were significantly higher (p<0.05) than those in NOE cells. OVOS2 mRNA levels in NOE001 and NOE002 were statistically the same, but the mean OVOS2/GAPDH for NOE002 was slightly higher (0.062 vs. 0.061). Fold increases in expression of OVOS2 relative to the NOE002 cells ranged from 3-(A2780) to 35-fold (OVCA432). We also measured the mRNA levels for A2M, A2ML1, and OVOS1 in the OVC and NOE cells (ESM Fig. S5 ) and did not observe consistently up-or downregulation for these genes across the cell types. OVOS2 protein expression in these cell lines was examined by Western blot analysis which confirmed the presence of high levels of OVOS2 protein at the predicted molecular weight of~165 kDa in all OVC cell lines but not in NOE cells (Fig. 4b) . The identity of the~165-kDa protein band as OVOS2 was verified by shRNA downregulation of OVOS2 expression in OVCA432 cells using two target specific sequences only found in OVOS2 mRNA (Fig. 4c) . We next used immunohistochemical staining to analyze the expression of OVOS2 in paraffin-embedded sections of stage III high-grade serous ovarian adenocarcinomas. As shown in Fig. 5 , all primary ovarian adenocarcinomas displayed intense OVOS2 staining in malignant epithelial cells while the surrounding non-cancerous tissues were not or only weakly stained
OVOS2 in chicken and human ovarian cancer
The interplay between proteases and endogenous inhibitors has been actively studied in relation to cancer for many years. The differential regulation of several protease inhibitors has been observed in ovarian cancer including serpins (i.e., SERPINA1/alpha 1-antitrypsin [66] , SERPINE1/plasminogen activator inhibitor-1 [67] , SERPINB2/plasminogen activator inhibitor-2 [68] , SERPINA5/plasminogen activator inhibitor-3 [69] , SERPINB5/maspin [70] ), tissue inhibitors of metalloproteases (TIMP) [71, 72] , secretory leukocyte protease inhibitor (SLPI) [73, 74] , and now OVOS2. The conventional view of cancer progression would suggest that upregulation of extracellular protease inhibitors like OVOS2 is a beneficial endogenous response to limiting the proteolysis of extracellular matrix proteins which contributes to metastasis. However, functional studies have shown that many endogenous protease inhibitors can actually promote cancer cell growth and metastasis through complex interactions or as indirect products from key regulators (e.g., colony stimulating factor 1 [67, 68] ). Finally, a recent study by Perets et al. [75] using a mouse model for fallopian tube-initiated OVC showed the BA2M region^of the mouse chromosome 6 was upregulated. This study adds to a growing literature that supports oviductal involvement in serous OVC [76] [77] [78] which runs counter to the established hypothesis that OVC originates from the ovarian surface epithelium (OSE) [79] . Thus, the upregulation of OVOS2 in chicken and human OVC suggests it plays a conserved role in OVC pathogenesis and possesses translational potential.
Conclusion
An in-depth label-free proteomics study of matched plasma, ovary, and oviduct tissues in the hen resulted in the quantification of over 2300 unique proteins, representing the most comprehensive proteomics study of ovarian cancer in the chicken to date. We identified 392 differentially regulated proteins in OVC plasma and ovarian tumor tissues including B2M, EPCAM, TPD52, CLDN3, and S100A6 which are established candidate biomarkers in human OVC. A 165-kDa protease inhibitor and candidate biomarker, OVOS2, a newly discovered protein in our laboratory, was detected at elevated levels in the plasma, ovaries, and oviduct of all latestage OVC birds in this study. Because OVOS2 is found in plasma and has biological relevance to cancer as a protease inhibitor, it was a candidate for translational studies in human OVC. Human OVOS2 expression at both mRNA and protein levels was found to be significantly upregulated in human OVC cell lines. OVOS2 immunohistochemical staining in primary stage III high-grade serous OVC tissue specimens showed strong staining in regions containing malignant epithelial cells while surrounding non-cancerous tissues were negative or only weakly stained. The combined indepth proteomics study of OVC in the chicken with targeted expression analysis of OVOS2 in human OVC biospecimens illustrates the power of this model for identifying novel differentially regulated proteins with translational potential. 
